🇺🇸 Anika Chebrolu

The year was 2020 and the world had stopped. Schools were closed, hospitals were overwhelmed, and virologists around the planet were racing against a pathogen no one fully understood. In Frisco, Texas, a fourteen-year-old girl named Anika Chebrolu sat at her computer and decided to join the race. She did not have a wet lab. She did not have a PhD. She had a laptop, molecular docking software, access to databases of small chemical compounds, and the focused intelligence of a mind that had been thinking about virology since before COVID-19 had a name. By October of that year, she would be named America's Top Young Scientist — and her work would attract the attention of researchers at institutions far larger than Nelson Middle School in Frisco.

Chebrolu's original research, begun in 2019, targeted influenza. Specifically, she was attempting to use computational methods to identify small molecules that could bind to hemagglutinin — the surface protein that influenza viruses use to attach to human cells and initiate infection. Her approach, called in-silico molecular docking, involves using software to model the three-dimensional structure of a target protein and then virtually screening thousands or millions of small molecules to find which ones have the highest binding affinity for specific sites on that protein. It is the computational equivalent of trying millions of keys in a lock, in seconds, and identifying the ones that fit best. No laboratory, no chemicals, no biological risk required.

When the COVID-19 pandemic reached Texas in the spring of 2020, Chebrolu pivoted. The SARS-CoV-2 virus uses a spike protein — a distinctive crown-like protrusion on its outer membrane — to bind to ACE2 receptors on human lung cells and gain entry. Block the spike protein, and you block the infection. This mechanism was already well understood by virologists; what the field needed was compounds that could disrupt it. Working with her 3M mentor, corporate scientist Dr. Mahfuza Ali, Chebrolu re-focused her in-silico screening pipeline on the SARS-CoV-2 spike protein.

The process she employed was rigorous and multi-stage. First, she screened millions of chemical compounds for drug-likeness — using Lipinski's Rule of Five and related pharmacological filters to eliminate molecules that would be metabolically unstable, toxic, or unable to cross biological membranes. Then she evaluated the surviving candidates for ADMET properties: absorption, distribution, metabolism, excretion, and toxicity. This narrowed the field substantially. From the remaining candidates, she ran molecular docking simulations to calculate binding affinity — the energetic "fit" between each small molecule and the receptor-binding domain of the spike protein. The molecule with the highest binding affinity and the best pharmacological profile — the one that, in simulation, would most effectively lock onto the spike protein and prevent it from interacting with human cells — became her lead compound.

This is computational drug discovery at a professional level. Pharmaceutical companies run exactly these pipelines, with teams of PhD researchers, supercomputing clusters, and multi-million dollar software licenses. Chebrolu ran hers on consumer hardware, with free or academic-access software, at fourteen. Her methodology was sound enough to be taken seriously by the scientific community, and her result — a specific small molecule identified as a potential therapeutic lead against COVID-19 — was exactly what the 3M Young Scientist Challenge judges evaluated when they awarded her the grand prize in October 2020: $25,000 and the title America's Top Young Scientist.

She also received the Improving Lives Award — given for the first time in competition history to recognize research with direct humanitarian impact. Chebrolu dedicated a portion of her prize to AcademyAid, a 501(c)(3) nonprofit she founded to provide educational supplies and STEM materials to underrepresented children worldwide. The molecule she identified has not, as of this writing, progressed through clinical trials to become an approved drug — in-silico findings are the first step in a long process, not the last. But as a demonstration of what a determined fourteen-year-old can do with computational tools and scientific training, it stands as one of the most remarkable achievements in the history of the 3M Young Scientist Challenge.

Anika Chebrolu received over three hundred interview requests in the weeks following her win. She handled them with the composure of a scientist who understood exactly what her research had and had not proven — careful about overclaiming, generous in explaining the methodology, clear-eyed about what comes next. That combination of scientific precision and human warmth is rarer than talent alone. It is what separates young scientists who make a single discovery from those who build careers.